Schedule of weighted-average life, original cost, accumulated amortization and net book value by major class |
|
|
|
Weighted-Average
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
Life (Years)
|
|
Original Cost
|
|
Amortization
|
|
Net Book Value
|
|
|
|
|
(in thousands)
|
|
|
Definite-lived intangible assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cortrosyn® product rights
|
|
12
|
|
$
|
27,134
|
|
$
|
24,461
|
|
$
|
2,673
|
|
|
IMS (UK) international product rights(1)
|
|
10
|
|
|
8,632
|
|
|
359
|
|
|
8,273
|
|
|
Acquired ANDAs(2)
|
|
15
|
|
|
4,000
|
|
|
222
|
|
|
3,778
|
|
|
Patents
|
|
10
|
|
|
293
|
|
|
137
|
|
|
156
|
|
|
Land-use rights
|
|
39
|
|
|
2,540
|
|
|
354
|
|
|
2,186
|
|
|
Other intangible assets
|
|
1
|
|
|
574
|
|
|
534
|
|
|
40
|
|
|
Subtotal
|
|
12
|
|
|
43,173
|
|
|
26,067
|
|
|
17,106
|
|
|
Indefinite-lived intangible assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trademark
|
|
*
|
|
|
29,225
|
|
|
—
|
|
|
29,225
|
|
|
Goodwill - Finished pharmaceutical products
|
|
*
|
|
|
3,976
|
|
|
—
|
|
|
3,976
|
|
|
Subtotal
|
|
*
|
|
|
33,201
|
|
|
—
|
|
|
33,201
|
|
|
As of December 31, 2016
|
|
*
|
|
$
|
76,374
|
|
$
|
26,067
|
|
$
|
50,307
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-Average
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
Life (Years)
|
|
Original Cost
|
|
Amortization
|
|
Net Book Value
|
|
|
|
|
(in thousands)
|
|
|
Definite-lived intangible assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cortrosyn® product rights
|
|
12
|
|
$
|
27,134
|
|
$
|
22,679
|
|
$
|
4,455
|
|
|
Patents
|
|
10
|
|
|
293
|
|
|
107
|
|
|
186
|
|
|
Land-use rights
|
|
39
|
|
|
2,540
|
|
|
288
|
|
|
2,252
|
|
|
Other intangible assets
|
|
1
|
|
|
590
|
|
|
533
|
|
|
57
|
|
|
Subtotal
|
|
12
|
|
|
30,557
|
|
|
23,607
|
|
|
6,950
|
|
|
Indefinite-lived intangible assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trademark
|
|
*
|
|
|
29,225
|
|
|
—
|
|
|
29,225
|
|
|
Goodwill - Finished pharmaceutical products
|
|
*
|
|
|
3,726
|
|
|
—
|
|
|
3,726
|
|
|
Subtotal
|
|
*
|
|
|
32,951
|
|
|
—
|
|
|
32,951
|
|
|
As of December 31, 2015
|
|
*
|
|
$
|
63,508
|
|
$
|
23,607
|
|
$
|
39,901
|
|
*Intangible assets with indefinite lives have an indeterminable average life.
(1)In August 2016, the Company acquired International Medication Systems (UK) Limited from UCB PHARMA GmbH for $7.7 million. The fair value of the marketing authorization was $9.2 million as of the acquisition date (see Note 3).
(2)In March 2016, the Company acquired 14 ANDAs representing 11 different injectable chemical entities from Hikma Pharmaceuticals PLC for $4.0 million (see Note 3). In February 2017, the Company sold the 14 ANDAs to an unrelated party purchaser for $6.4 million (see note 18).
|
Schedule of changes in carrying amounts of goodwill |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
|
|
2016
|
|
2015
|
|
|
|
|
|
(in thousands)
|
|
|
Beginning balance
|
|
|
$
|
3,726
|
|
$
|
4,467
|
|
|
Goodwill related to acquisition of business
|
|
|
|
391
|
|
|
—
|
|
|
Currency translation and other adjustments
|
|
|
|
(141)
|
|
|
(741)
|
|
|
Ending balance
|
|
|
$
|
3,976
|
|
$
|
3,726
|
|
|
Schedule of finite-lived intangible assets, future amortization expense |
|
|
|
|
|
|
|
|
|
(in thousands)
|
|
|
2017
|
|
$
|
2,650
|
|
|
2018
|
|
|
1,759
|
|
|
2019
|
|
|
857
|
|
|
2020
|
|
|
851
|
|
|
2021
|
|
|
851
|
|
|
Thereafter
|
|
|
10,138
|
|
|
Total amortizable intangible assets
|
|
|
17,106
|
|
|
Indefinite-lived intangibles
|
|
|
33,201
|
|
|
Total intangibles (net of accumulated amortization)
|
|
$
|
50,307
|
|
|